NexImmune Inc. NexImmune Granted Key US Patent for Core E+E Technology December 11, 2018
Read More
NuMat Technologies, Inc NuMat Technologies Partnership to Protect and Sustain Modern Warfighter with Dual-Use Technology December 7, 2018
Poseida Therapeutics Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting P-BCMA-101 showed a 100% ORR with…
Bellicum Pharmaceuticals, Inc. Bellicum Announces Data Presentation at ASH 2018 Demonstrating Low Rates of Cancer Recurrence in Pediatric AML and ALL Patients Treated with Rivo-cel Results show high rates of…
Bellicum Pharmaceuticals, Inc. Bellicum Announces Favorable Interim Event-Free Survival Data for Rivo-cel Treated Patients in Presentation at ASH 2018 Interim results suggest rivo-cel outcomes were comparable to a control study…
Bellicum Pharmaceuticals, Inc. Bellicum Announces Interim Results Showing Rimiducid Controlled GvHD in Patients Treated with Rivo-cel Following a Stem Cell Transplant Experience to date in clinical study shows high clinical…
Poseida Therapeutics FDA Grants Poseida’s P-BCMA-101 Regenerative Medicine Advanced Therapy (RMAT) Status for Treatment of Multiple Myeloma November 19, 2018
AsclepiX Therapeutics AsclepiX Therapeutics Raises $5M in New Funding Financing will advance clinical development of the Company’s lead product AXT107 November 15, 2018
AsclepiX Therapeutics Baltimore-based AsclepiX Therapeutics raises $5M The Johns Hopkins spinout is developing a new treatment for leading causes of blindness. November 15, 2018
angelMD angelMD Investor Group Closes Funding Round with Indago November 13, 2018